The FY19 Defense Appropriations Act provides $15 million to the Department of Defense Neurofibromatosis Research Program to support innovative, high-impact NF research.
The FY19 Defense Appropriations Act provides $15 million (M) to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research. Applications to the FY19 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
FY19 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
https://cdmrp.army.mil/
Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY19 Areas of Emphasis. Not all Areas of Emphasis are applicable to each award mechanism offered by the FY19 NFRP. If the proposed research project does not address one of the FY19 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.
- Health services research
- Evidence-based best clinical practices
- Outcomes of specific therapies, including surgery and radiation therapy
- Implementation and access to NF-specific healthcare
- Utilization of technology and informatics
- Evidence-based best clinical practices
- Heterogeneity of NF-related tumors
- Non-tumor manifestations
- Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations
- Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
